Volume: 4 Issue: 1 , 12/31/22

Year: 2022

Letter to Editor

Letter to Editor

1. Tips for Eyelid Lacerations

Letter to Editor

2. Textbook of Eye Diseases in The Light of Current Information

Research Article

Case Report

Clinical and Experimental Ocular Trauma and Infection is a double blind peer-reviewed scientific electronical  journal. The language of the journal is English. One issue will be published annually. A manuscript will be considered only with the understanding that it is an original contribution that has not been published elsewhere. CEOTI is indexing in DOAJ.

The abbreviation of the Clinical and Experimental Ocular Trauma and Infection is CEOTI. Clinical and Experimental Ocular Trauma and Infection is a open access journal and it is a free of charge journal to both authors and readers. All content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the  Budapest Open Access Initiative's  definition of open access

The aim of the CEOTI is to develop a scientific platform for discussing ocular traumas and ocular infections.  

Clinical and Experimental Ocular Trauma and Infection is a scientific journal that is focused on every aspect of ocular traumas, treatments, rehabilitation, protection, and every aspect of ocular infections, treatments both in children and adults. Additionally new experimental models for trauma and infection and experimental studies for understanding effects of the trauma and infection on eye are within the Scope of the journal.

            Clinical and Experimental Ocular Trauma and Infection is a double blind peer-reviewed, scientific electronical journal. The language of the journal is English. One issue will be published annually. A manuscript will be considered only with the understanding that it is an original contribution that has not been published elsewhere. The mailing abbreviation of the Clinical and Experimental Ocular Trauma and Infection is CEOTI for ; however according to ISSN record the abbreviation ¨Clin Exp Ocul Trauma Infect¨ should be used while citing a publication from this journal. Clinical and Experimental Ocular Trauma and Infection is a open access journal and it is a free of charge journal to both authors and readers. Clinical and Experimental Ocular Trauma and Infection is a scientific journal that is focused on every aspect of ocular traumas, treatments, rehabilitation, protection, and every aspect of ocular infections, treatments both in children and adults. Additionally new experimental models for trauma and infection and experimental studies for understanding effects of the trauma and infection on eye are within the Scope of the journal. CEOTI is indexing in DOAJ.

 

The copyright of the manuscripts belongs to Clinical and Experimental Ocular Trauma and Infection. All manuscripts submitted for publication must be accompanied by the Copyright Form. Corresponding author has responsibility about correctness of the data, copyrights, declaration of conflict of interests, and corresponding author must sign on behalf of all contributing authors. On the one hand it shows a declaration of all authors that the content of the manuscript and/or the data have not been submitted elsewhere or previously published, on the other hand it is a declaration that states scientific contributions and responsibilities of all authors. The studies that are presented in a meeting and published as meeting abstracts should be mentioned in the title page. Also any financial disclosure or any relationship with the, drug or pharmaceutical company, and commercial product and statement of conflict of interest should be mentioned in the title page.


Publication ethics: Clinical and Experimental Ocular Trauma and Infection follows International Committee of Medical Journals Editors` (ICMJE) Recommendations (http://www.icmje.org/recommendations/) and Committee on Publication Ethics` (COPE) (https://publicationethics.org) international standards for editors and authors. All manuscripts submitted to Clinical and Experimental Ocular Trauma and Infection are screened for plagiarism using the ‘iThenticate’ software. Results indicating plagiarism may result in manuscripts being returned or rejected.

Experimental animal studies should be approved by animal ethic committee according to Guide for the Care and Use of Laboratory Animals (http://oacu.od.nih.gov/regs/guide/guide.pdf), clinical studies, clinical trials and new drug studies should be approved by ethical board. Approval reports sholud be submitted to the journal. Authors must declare that the study was conducted in accordance with international agreements and the Declaration of Helsinki.

The Clinical and Experimental Ocular Trauma and Infection  is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation are sent for external peer review, and the Editor-in-Chief can evaluate the manuscripts himself/herself or can assign an Associate Editor. Then manuscripts are  sent to at least two reviewers. The reviewers must review the manuscript within 4 weeks. The Associate Editor recommends a decision based on the reviewers’ recommendations and returns the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.

Accepted types of manuscripts: Research article (both clinical and experimental), mini review, review, case reports, short communication, letter to the editor, technical methods (brief), book review, clinical image, photo quiz

Preparation of  articles(clinical and experimental research, systematic reviews, meta-analyses...etc.) must comply with study design guidelines:

Randomized controlled trials : Consort statement  (http://www.consort-statement.org/)

Systematic reviews and meta-analyses: PRISMA statement (http://www.prisma-statement.org/)

Reporting of studies of diagnostic accuracy: STARD statement (http://www.stard-statement.org/)

A checklist for reports of observational studies: STROBE statement (http://www.strobe-statement.org/);

meta-analysis and systemic reviews of observational studies: MOOSE guidelines

General Requirements

Manuscripts can only be submitted electronically via CEOTI web site.

 To submit your study please click this link: manuscript submission 

Language of the journal is English, manuscripts should be written as word document with Arial font. Font size should be 12. Margins should be 2.5 cm from all sides. There should be 1.5 line space between lines.

A title page should be written for all kind of manuscripts. A structured abstract  is also necessary for all studies except clinical image, short communication, review, book review and photoquiz. Submission of a cover letter is optional. 

Title Page: Title page must contain a title, a running title, authors names, authors affiliations, corresponding author information (name, address, telephone number and e-mail address of corresponding author), financial disclosure, conflict of interest statement, funding sources.

Abstract: Manuscripts should be submitted with a structured abstract. Abstracts sections should be Purpose, Material and Methods, Results and Conclusion. A structured abstract is also necessary for all studies except, review, clinical image, short communication, book review and photo quiz.

 

Orginal article: This section should be organized as structured Abstract, Introduction, Material and method, Results, Discussion, References. Number of references should not exceed 45.

Review and mini review article: This section should be organized as un-structured Abstract, Introduction, Material and method, Results and subtitles of the topics, Discussion, References. There is no reference limitation.

Case Reports: This section should be organized as structured Abstract, Introduction, Case presentation,  Discussion, References. Number of references should not exceed 35.

Letter to the Editor: The word count of this section should not  exceed 1500 words. Number of references should not exceed 6.

Short Communication: The word count of this section should not  exceed 2000 words. Number of references should not exceed 10. A new surgical technique, experimental study technique, an important issue about ocular trauma and ocular infection or new treatment modalities can be submitted as short communication.

Clinical image: The word count of this section should not be exceed 500 words. Maximum 3 image should be submitted.

 

References: References should be numbered with Arabic numerals in the order in which they appear in the text in round bracket, end of the sentence just after dot. In references list surnames and first letter of names of first three author should be written. There must be a coma between names. If the Author number is more than 6, "et al"  should be added end of the name list. Then title of the study should be written. After title, abbreviated journal name according to the List of Title Word Abbreviations (http://www.issn.org/services/online-services/access-to-the-ltwa/) must be added. Publication year, volume, issue and pages should be added to the end. Doi numbers should not be written in the text in the references part, but at submission if there is a doi for that a reference it can be added to doi section. Authors are responsible for the accuracy of the references.


Examples:

Journal: Sherwood D, Sponsel WE, Lund BJ, Gray W, Watson R, Groth SL et al. Anatomical manifestations of primary blast ocular trauma observed in a postmortem porcine model. Invest Ophthalmol Vis Sci. 2014;55(2):1124-32. 


Book: Kuhn F. Ocular traumatology (1st ed). Heilderberg; Springer; 2008. 


Book Chapter: Kuhn F, Morris R, Witherspoon CD. BETT: The terminology of ocular trauma. In: Kuhn F, Pieramici DJ eds. Ocular trauam: Principles and practice (1st ed). New York; Thieme; 2002: 3-5. 


Tables, Graphics, Figures: All tables, graphics or figures should be enumerated 
in the order in which they appear in the text. A caption should be written. In particular they should be clear and understandable. 

Tables: Should be submitted separately in a word document. If the study be accepted, authors must send latest version as a tiff format.

Figures: Should be submitted separately as a jpeg or tiff. Minimum resolution should be 300 dpi. Figure legend also should be written after reference list.

 

Open Access Policy

Clinical and Experimental Ocular Trauma and Infection is a open access journal and it is a free of charge journal to both authors and readers. All content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author, with no financial, legal, or technical barriers. This is in accordance with the  Budapest Open Access Initiative's  (BOAI) (http://www.budapestopenaccessinitiative.org/) definition of open access.  The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

Journal Advertising Policy: Journal do not accept any type of advertisement.



Publication ethics: Clinical and Experimental Ocular Trauma and Infection follows International Committee of Medical Journals Editors(ICMJE)Recommendations (http://www.icmje.org/recommendations/) and  Committee on Publication Ethics (COPE) (https://publicationethics.org) international standards for editors and authors. All manuscripts submitted to Clinical and Experimental Ocular Trauma and Infection are screened for plagiarism using the ‘iThenticate’ software. Submitted manuscripts are also subjected for the evaluation of plagiarism, duplicate publication by automatic software. Authors are obliged to acknowledge if they published study results in full or in part in form of abstracts. Results indicating plagiarism may result in manuscripts being returned or rejected.

Plagiarism: To re-publish whole or in part the contents of another author's publication as one's own without providing a reference.

Fabrication: To publish data and findings/results that do not exist. Duplication: Use of data from another publication, which includes re-publishing a manuscript in different languages. Salamisation: To create more than one publication by dividing the results of a study preternaturally. We disapproval upon such unethical practices as plagiarism, fabrication, duplication, and salamisation, as well as efforts to influence the review process with such practices as gifting authorship, inappropriate acknowledgements, and references. Additionally, authors must respect participant right to privacy.


Experimental animal studies should be approved by animal ethic committee according to Guide for the Care and Use of Laboratory Animals (http://oacu.od.nih.gov/regs/guide/guide.pdf), clinical studies, clinical trials and new drug studies should be approved by ethical board. Approval reports sholud be submitted to the journal. Authors must declare that the study was conducted in accordance with international agreements and the Declaration of Helsinki.


The Clinical and Experimental Ocular Trauma and Infection is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation are sent for external peer review, and the Editor-in-Chief can evaluate the manuscripts himself/herself or can assign an Associate Editor. Then manuscripts are sent to at least two reviewers. The reviewers must review the manuscript within 4 weeks. The Associate Editor recommends a decision based on the reviewers’ recommendations and returns the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.

CEOTI is an Open Access journal, and article submission/process management and accessing all articles is free of charge.

Citation Indexes

Other Indexes

Honorary Editor in Chief

Honorary Editor in Chief
Default avatar
Prof. Dr. Ferenc KUHN University of Alabama, Birmingham

Editor in Chief

Prof. Dr. Sertaç Argun KIVANÇ Bursa Uludag University, School of Medicine, Department of Ophthalmology
Infectious Agents, Ophthalmology and Optometry, Health Sciences
Prof. Dr. Berna AKOVA Uludag University, Department of Ophthalmology; Bursa
Infectious Agents, Ophthalmology, Health Sciences

Editorial Board

Editör Kurulu
Default avatar
Prof. Dr. Berna AKOVA Uludag University, Department of Ophthalmology; Bursa
Default avatar
Prof. Dr. Sertaç Argun KIVANÇ Bursa Uludag University, School of Medicine, Department of Ophthalmology
Default avatar
Dr. Angelina MEİRELES Centro Hospitalar Universitário do Porto - HSA, Porto
Hugo Hernan Ocampo
Dr. Hugo Hernan OCAMPO Clinica de Ophthalmologia de Cali, Universidad del Valle, Cali
Default avatar
Prof. Dr. Wolfgang SCHRADER Augenzentrum, Würzburg
Default avatar
Prof. Dr. Remzi AVCI Retina Eye Hospital
Default avatar
Prof. Dr. Sundaran NATARAJAN Aditya Jyot Eye Hospital, New Delhi
Default avatar
Prof. Dr. Merih KIVANÇ Eskisehir Technical University, Faculty of Science, Eskişehir
Default avatar
Prof. Dr. Gülay GÜLLÜLÜ It is not affiliated with an institution
Mehmet Çıtırık
Prof. Dr. Mehmet ÇITIRIK Department of Ophthalmology, University of Health Sciences, Ankara Etlik City Hospital
Default avatar
Dr. Eduardo Büchele RODRİGUES Universidade Federal de São Paulo
Default avatar
Prof. Dr. Mehmet CANSEV ULUDAG UNIVERSITY, FACULTY OF MEDICINE
Default avatar
Prof. Dr. Erdal YÜZBAŞIOĞLU Istanbul Bilim University, School of Medicine, Department of Ophthalmology
Default avatar
Dr. Viladimir PFEİFER Dr Pfeifer Eye Surgery Center, Ljubljana
Default avatar
Prof. Dr. Tarek HASSAN Oakland University William Beaumont School of Medicine, USA

Editors

Default avatar
Prof. Dr. Sertaç Argun KIVANÇ Bursa Uludag University, School of Medicine, Department of Ophthalmology
Infectious Agents, Ophthalmology and Optometry, Health Sciences
Default avatar
Prof. Berna AKOVA Bursa Uludağ Üniversitesi
Ophthalmology and Optometry

Layout Editor

Sezin Türk Kaya
Prof. Sezin TÜRK KAYA Bursa Uludağ Üniversitesi

Statistics Editor

Gökhan Ocakoğlu
Prof. Dr. Gökhan OCAKOĞLU ULUDAG UNIVERSITY, FACULTY OF MEDICINE, DEPARTMENT OF BIOSTATISTICS Web
Statistics, Biostatistics

Technical and Author Support

Default avatar
Prof. Dr. Sertaç Argun KIVANÇ Bursa Uludag University, School of Medicine, Department of Ophthalmology
Infectious Agents, Ophthalmology and Optometry, Health Sciences

Editorial Board

Default avatar
Dr. Angelina MEİRELES Centro Hospitalar Universitário do Porto - HSA, Porto
Ophthalmology, Health Sciences
Default avatar
Prof. Dr. Merih KIVANÇ Eskisehir Technical University, Faculty of Science, Eskişehir
Bacteriology, Mycology, Mathematical Sciences, Health Sciences, Agricultural Biotechnology Diagnostics
Francesc March De Ribot
Specialist Francesc MARCH DE RİBOT It is not affiliated with an institution

Consultant ophthalmology and researcher. University Hospital. 

Ophthalmology and Optometry
Default avatar
Prof. Dr. Berna AKOVA Uludag University, Department of Ophthalmology; Bursa
Infectious Agents, Ophthalmology, Health Sciences
Default avatar
Prof. Dr. Sertaç Argun KIVANÇ Bursa Uludag University, School of Medicine, Department of Ophthalmology
Infectious Agents, Ophthalmology and Optometry, Health Sciences
Default avatar
Assoc. Prof. Mahmut Oğuz ULUSOY SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, BURSA YÜKSEK İHTİSAS SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ
Ophthalmology, Health Sciences
Default avatar
Assoc. Prof. Osman Okan OLCAYSÜ UNIVERSITY OF HEALTH SCIENCES, İSTANBUL BAKIRKÖY DR. SADİ KONUK TRAINING RESEARCH CENTER
Ophthalmology and Optometry, Ophthalmology
Default avatar
Prof. Dr. Gülay GÜLLÜLÜ It is not affiliated with an institution
Ophthalmology, Health Sciences
My ultimate goal as a clinician-scientist is to improve vision in children and adults with retinal disorders. As a clinician, I specialize in diseases and surgery of the retina and vitreous as well as management of acquired and inherited pediatric retinal disorders. I’ve had extensive medical and surgical training in vitreoretinal disorders, including macular degeneration, retinal dystrophies and complex adult and pediatric vitreoretinal surgery. As a basic research scientist, I have been studying the molecular mechanisms of apoptosis and survival during periods of neuronal and retinal stress for over 16 years. My PhD training in neuronal apoptosis and post-PhD work in photoreceptor cell death has provided me with a unique expertise in designing, executing and analyzing cell death and survival assays in different experimental paradigms, including various cell lines and in vivo models of neuronal and retinal diseases in rodents. I have used these models extensively to identify small molecule inhibitors of apoptosis in cell lines, primary neurons, and photoreceptors. My current work focuses primarily on the metabolic regulation of photoreceptor death. Proteomic analysis of the subretinal fluid samples collected from children and adults with retinal detachment identified key metabolic proteins as potential mediators of photoreceptor cell death. Based on this observation, I generated in vitro and in vivo models to study metabolic regulation of photoreceptor death and demonstrated that metabolic reprogramming is a novel strategy for photoreceptor neuroprotection in retinal degeneration.
Ophthalmology and Optometry, Vision Science
Default avatar
Prof. Dr. Kadriye Ufuk ELGİN It is not affiliated with an institution
Ophthalmology and Optometry